| Abbreviation |
Full Name |
| ACTG |
AIDS Clinical Trials Group |
| AIDS |
acquired immune deficiency syndrome |
| ALT |
alanine aminotransferase |
| ART |
antiretroviral therapy |
| ART-CC |
ART Cohort Collaboration |
| ARV |
antiretroviral |
| AST |
aspartate aminotransferase |
| AUC |
area under the curv |
| AV |
atrioventricular |
| |
|
| bDNA |
branched DNA |
| BID |
twice daily |
| BMD |
bone mineral density |
| BMI |
body mass index |
| BUN |
blood urea nitrogen |
| |
|
| cap |
capsule |
| CAPD |
chronic ambulatory peritoneal dialysis |
| CBC |
complete blood count |
| CCB |
calcium channel blocker |
| CDC |
Centers for Disease Control and Prevention |
| CI |
confidence interval |
| CKD |
chronic kidney disease |
| Cmax |
maximum plasma concentration |
| CME |
continuing medical education |
| Cmin |
minimum plasma concentration |
| CMV |
cytomegalovirus |
| CNICS |
Centers for AIDS Research Network of Integrated Clinical Systems |
| CNS |
central nervous system |
| COC |
combined oral contraceptives |
| CPK |
creatine phosphokinase |
| CrCl |
creatinine clearance |
| CSF |
cerebrospinal fluid |
| CVD |
cardiovascular disease |
| CYP |
cytochrome P |
| |
|
| D/M |
dual or mixed (tropic) |
| D:A:D |
Data Collection on Adverse Events of Anti-HIV Drugs Study |
| DILI |
drug-induced liver injury |
| DM |
diabetes mellitus |
| DMPA |
depot medroxyprogesterone acetate |
| DOT |
directly observed therapy |
| DR |
delayed release |
| DXA |
dual-energy x-ray absorptiometry |
| |
|
| EBV |
Epstein-Barr virus |
| EC |
enteric coated |
| ECG |
electrocardiogram |
| EI |
entry inhibitor |
| EIA |
enzyme immunoassay |
| |
|
| FDA |
Food and Drug Administration |
| FI |
fusion inhibitor |
| |
|
| GHB |
gamma-hydroxybutyrate |
| GI |
gastrointestinal |
| |
|
| HAD |
HIV-associated dementia |
| HAV |
hepatitis A virus |
| HBeAg |
hepatitis B e antigen |
| HBsAg |
hepatitis B surface antigen |
| HBV |
hepatitis B virus |
| HCV |
hepatitis C virus |
| HD |
hemodialysis |
| HDL |
high-density lipoprotein |
| HELLP |
hemolysis, elevated liver enzymes, low platelet count (syndrome) |
| HHS |
Department of Health and Human Services |
| HHV |
human herpes virus |
| HHV-8 |
human herpes virus-8 |
| HIV |
human immunodeficiency virus |
| HIV-1 |
human immunodeficiency virus type 1 |
| HIV-2 |
human immunodeficiency virus type 2 |
| HIVAN |
HIV-associated nephropathy |
| HLA |
human leukocyte antigen |
| HPV |
human papilloma virus |
| HR |
hazard ratio |
| HRSA |
Health Resource Services Administration |
| hsCRP |
high-sensitivity C-reactive protein |
| HSR |
hypersensitivity reaction |
| HTLV |
human T-cell leukemia virus |
| HTLV-1 |
human T-cell leukemia virus type 1 |
| HTLV-2 |
human T-cell leukemia virus type 2 |
| |
|
| IAS-USA |
International Antiviral Society-USA |
| IC |
inhibitory concentration |
| IDU |
injection drug user |
| IFN-γ |
interferon-gamma |
| IGRA |
interferon-gamma release assay |
| IL-2 |
interleukin-2 |
| IL-6 |
interleukin-6 |
| IL-7 |
interleukin-7 |
| IND |
investigational new drug |
| INH |
isoniazid |
| inj |
injection |
| INR |
international normalized ratio |
| INSTI |
integrase strand transfer inhibitor |
| IQ |
inhibitory quotient |
| IRB |
Institutional Review Board |
| IRIS |
immune reconstitution inflammatory syndrome |
| IUD |
intrauterine device |
| IV |
Intravenous |
| |
|
| LDL |
low-density lipoprotein |
| LTBI |
latent tuberculosis infection |
| |
|
| MAC |
Mycobacterium avium complex |
| MDMA |
methylenedioxymethamphetamine |
| mDOT |
modified directly observed therapy |
| MDR |
multidrug-resistant |
| MDRD |
modification of diet in renal disease (equation) |
| MHC |
major histocompatability complex |
| MI |
myocardial infarction |
| msec |
milliseconds |
| MSM |
men who have sex with men |
| MTB |
Mycobacterium tuberculosis |
| MTCT |
mother-to-child transmission |
| |
|
| NA-ACCORD |
The North American AIDS Cohort Collaboration on Research and Design |
| NIH |
National Institutes of Health |
| NNRTI |
non-nucleoside reverse transcriptase inhibitor |
| NRTI |
nucleoside reverse transcriptase inhibitor |
| |
|
| OAR |
Office of AIDS Research |
| OARAC |
Office of AIDS Research Advisory Council |
| OI |
opportunistic infection |
| |
|
| PAH |
pulmonary arterial hypertension |
| PCP |
Pneumocystis jiroveci pneumonia |
| PDE5 |
phosphodiesterase type 5 |
| PegIFN |
peginterferon |
| p-gp |
p-glycoprotein |
| PI |
protease inhibitor |
| PK |
pharmacokinetic |
| PMTCT |
prevention of mother-to-child transmission |
| PNS |
peripheral nervous system |
| PO |
orally |
| PPI |
proton pump inhibitor |
| PR |
protease (gene) |
| PrEP |
pre-exposure HIV prophylaxis |
| PT |
prothrombin time |
| |
|
| QTc |
QT corrected for heart rate |
| |
|
| RT |
reverse transcriptase (gene) |
| RT-PCR |
reverse transcriptase-polymerase chain reaction |
|
|
| SJS |
Stevens-Johnson syndrome |
| soln |
solution |
| SPT |
skin patch test |
| STD |
sexually transmitted disease |
| SVR |
sustained virologic response |
| SWP |
suggested wholesale price |
| |
|
| t1/2 |
half-life |
| tab |
tablet |
| TAM |
thymidine analogue mutation |
| TB |
tuberculosis |
| TCA |
tricyclic antidepressant |
| TDM |
therapeutic drug monitoring |
| TEN |
toxic epidermal necrosis |
| TG |
triglyceride |
| the Panel |
Panel on Antiretroviral Guidelines for Adults and Adolescents |
| TID |
three times daily |
| |
|
| UDP |
uridine diphosphate |
| UGT |
uridine diphosphate gluconyltransferase |
| UGT1A1 |
uridine diphosphate glucuronosyltransferase 1A1 |
| ULN |
upper limit of normal |
| |
|
| VPA |
valproic acid |
| |
|
| WBC |
white blood cell |
| WHO |
World Health Organization |
| WITS |
Women and Infants Transmission Study |
| |
|
| XDR |
extensively drug-resistant |
| XR |
extended release |
| |
|